BioGrid

BioGrid introduces a groundbreaking organ-on-chip platform that transforms preclinical drug development by combining versatility, scalability, and ease of use. Each chip—no larger than a standard microscopy slide—integrates 96 miniaturized tissue models, enabling high-throughput testing across a wide range of cell and tissue types while drastically reducing the need for scarce materials.

Developed at Radboudumc by experts in biomaterials, microfluidics, and 3D tissue modeling, BioGrid represents a major leap forward in organ-on-chip technology. With its patented design and demonstrated interest from leading industry players such as Charles River Laboratories, BioGrid is positioned to become the new gold standard for efficient, automated, and predictive drug screening in a €1B+ global market.